, , , , , , , ,


Eric A. Singer, MD, MA, FACS, urologic oncologist at Rutgers Cancer Institute and assistant professor of surgery at Rutgers Robert Wood Johnson Medical School, is the lead researcher on the study at the Cancer Institute. “For patients with advanced stages of kidney cancer, effective treatment options are limited.  By exploring therapies that harness one’s own immune system, there is an opportunity to address an unmet need in this patient population,” he said.

Read the full story here.